Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 17/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425143 | 0.92 | LIPE (0.43) | TRPV4CYP3A4KCNH2TRPM8LIPE | |
| SCHEMBL5438850 | 0.89 | HSD11B1 (0.41) | TRPV4CYP3A4KCNH2TRPM8CYP19A1 | |
| SCHEMBL5421695 | 0.87 | USP2 (0.45) | TRPV4CYP3A4HSD11B1 | |
| SCHEMBL5422092 | 0.87 | TRPV4 (0.46) | TRPV4CYP3A4KCNH2TRPM8 | |
| SCHEMBL5431215 | 0.86 | TRPV4 (0.45) | TRPV4CYP3A4KCNH2TRPM8 | |
| SCHEMBL5437244 | 0.85 | LIPE (0.46) | TRPV4LIPE | |
| SCHEMBL5431071 | 0.81 | CYP3A4 (0.46) | CYP3A4CYP19A1 | |
| SCHEMBL5423744 | 0.80 | L3MBTL1 (0.46) | CYP3A4LIPEHSD11B1 | |
| SCHEMBL5425193 | 0.79 | SLC13A5 (0.40) | CYP3A4LIPEHSD11B1 | |
| SCHEMBL5421659 | 0.77 | MAPT (0.44) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | claimed |
| EP-1683797-A1 | HETEROCYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | claimed |
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | disclosed |
| EP-1683797-A1 | HETEROCYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | NR3C2, CBR1, CBR3 | TRPV4 3352/4885CYP3A4 888/4885KCNH2 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.